(News Bulletin 247) – To meet the challenges of health sovereignty, Euroapi is announcing several initiatives to increase its production capacity for several active pharmaceutical ingredients appearing on the list of essential medicines established by the French authorities.
Via its Francopia subsidiary dedicated to controlled substances, it will invest in R&D activities at its Vertolaye site (Puy-de-Dôme) to increase, by 2027, its production of morphine and its derivatives, as well as their antagonists used as antidotes.
The total amount of investments could reach 70 million euros, of which approximately 15% for R&D and 85% for industrial investments which would be deployed from 2026. They will benefit, in part, from the financial support of the State via France 2030.
In addition, within the framework of the Important Project of Common European Interest (IPCEI) currently being examined by the European Commission, Euroapi has proposed innovative projects to help cover, by 2030, the needs for macrolide antibiotics and corticosteroids.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
